Clinical trial

A Phase 3, Single-arm Study Evaluating the Safety and Effectiveness of VX-548 for Acute Pain

Name
VX22-548-107
Description
The purpose of this study is to evaluate the safety and effectiveness of VX-548 in treating acute pain.
Trial arms
Trial start
2023-01-09
Estimated PCD
2023-12-12
Trial end
2023-12-12
Status
Completed
Phase
Early phase I
Treatment
VX-548
Tablets for oral administration.
Arms:
VX-548
Other names:
Suzetrigine
Size
258
Primary endpoint
Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Day 1 up to Day 28
Eligibility criteria
Key Inclusion Criteria: * Body mass index (BMI) of greater than or equal to (≥) 18.0 to less than (\<) 40.0 kilogram per meter square (kg/m\^2) * Non-surgical participants with pain of new origin (not related to a prior known condition) that is moderate or severe on the verbal categorical rating scale (VRS) and ≥4 on the numeric pain rating scale (NPRS) * Surgical participants reporting pain at the surgical site that is moderate or severe on the VRS and ≥4 on the NPRS Key Exclusion Criteria: * Surgical participants: * History of previous surgery due to the same condition, except for procedures for which a previous surgery on the contra-lateral limb or organ is allowed * History of a prior surgical procedure in the same region of the body that resulted in any perioperative complications or that, in the opinion of the investigator or medical monitor, would preclude participation in the study * History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant Other protocol defined Inclusion/Exclusion criteria may apply.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 258, 'type': 'ACTUAL'}}
Updated at
2024-03-20

1 organization

1 product

1 indication

Product
VX-548
Indication
Pain